Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), filed a Form 4 on November 17, 2026, disclosing a sale of 854 shares of common stock on November 16, 2026, under a Rule 10b5-1 trading plan.
Key Highlights
- Transaction date: 854 shares of common stock were disposed of on November 16, 2026, at a price of $45.48 per share.
- Rule 10b5-1 plan: The filing indicates the transaction was made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).
- Source of shares: According to the filing, the shares were originally acquired through a purchase under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2025.
- Post-transaction ownership: Following the reported transaction, Donovan beneficially owned 8,139 shares of common stock directly.
- ESPP shares included: The post-transaction total includes 368 shares purchased on November 16, 2026, pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- Signed by attorney-in-fact: John R. Moore signed the form as attorney-in-fact for Joanne M. Donovan on November 17, 2026.
Donovan's November 2026 Share Disposition and Resulting Holdings at Edgewise Therapeutics
According to the Form 4 filed with the SEC on November 17, 2026, Joanne M. Donovan, who serves as Chief Medical Officer of Edgewise Therapeutics, Inc., disposed of 854 shares of the company's common stock on November 16, 2026. The transaction code recorded is "S," indicating a sale, at a reported price of $45.48 per share. The filing notes the transaction was made pursuant to a Rule 10b5-1(c) plan, as indicated by the checked box on the form.
The filing states that the disposed shares were originally acquired through a purchase under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2025. Separately, the filing discloses that 368 shares were purchased on November 16, 2026, also under the 2021 Employee Stock Purchase Plan, and those shares are included in the post-transaction beneficial ownership figure of 8,139 shares held directly.
No derivative securities transactions were reported in Table II of the filing. The form was signed by John R. Moore as attorney-in-fact for Donovan on November 17, 2026. The filing covers only direct ownership; no indirect beneficial ownership positions were disclosed.
What Was Disclosed
The filing reports a sale of 854 common shares by Edgewise Therapeutics' CMO, Joanne M. Donovan, at $45.48 per share on November 16, 2026, under a Rule 10b5-1 plan, leaving her with 8,139 shares of direct beneficial ownership.



Please wait processing your request...